Article Details
Retrieved on: 2023-09-15 17:19:36
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
The company also said that enrollment is now complete for its phase 3 safety and immunogenicity trial for the updated formulation of mRNA-1010 (P303).
Article found on: www.patientcareonline.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here